PDS Biotechnology(美國)

PDS Biotechnology

美國PDSBiotechnologywww.pdsbiotech.comPDSBiotechnologyCorporation是一家非上市生物技術(shù)公司，致力于通過利用帶陽電荷的特殊合成脂質(zhì)中新發(fā)現(xiàn)的屬性來推廣新一代免疫療法和疫苗。專有的Versamune™平臺納米技術(shù)，一旦與具體癌癥相關(guān)的分子相結(jié)合，經(jīng)證實(shí)與臨床前癌癥模式中的臨床輔助治療相比，可實(shí)現(xiàn)更高的腫瘤衰退率（CancerImm unologyImmunotherapy,2008,57:(4)517-530）。Versamune™納米技術(shù)在開發(fā)新一代免疫療法方面實(shí)現(xiàn)了巨大了進(jìn)步。PDSBiotechnologyCorporation正在開發(fā)治療子宮癌、頭頸癌和黑瘤等多發(fā)癌癥的主打產(chǎn)品。該技術(shù)還被用于開發(fā)預(yù)防流行病的疫苗。PDSBiotechnologyCorporationisaprivatelyheldbiotechnologycompanyfoundedtoexploitthenewlydiscoveredpropertiesofspecificsyntheticpositivelycharged(cationic)lipidstocommercializeanewgenerationofimmunotherapiesandvaccines.TheproprietaryVersamune™platformnanotechnology,whencombinedwithspecificcancer-associatedmolecules,hasbeendemonstratedtoleadtoincreasedtumorregressionratescomparedtoleadingclinicaladjuvantsinpre-clinicalcancermodels(CancerImmunologyImmunotherapy,2008,57:(4)517-530).TheVersamune™nanotechnologypresen